DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
PlushCare's weight loss program offers GLP-1 prescriptions through its primary care telehealth platform.
A legitimate doctor-led GLP-1 gateway, not a discount pharmacy
PlushCare Weight Loss is worth it if you want a board-certified physician (rather than a nurse practitioner) to evaluate you, order proper labs, and prescribe a GLP-1 medication such as brand-name Wegovy or Zepbound. PlushCare leads with FDA-approved brand drugs and offers more of them than most competitors. It can also prescribe compounded semaglutide or tirzepatide in eligible states, typically as a cheaper cash-pay route when insurance denies a brand drug, so it is not a brand-only clinic. Either way, PlushCare mainly handles the consult and prescription: the medication itself is a separate cost that ranges from a few hundred dollars on cash-pay or compounded pricing to roughly $1,000+ per month at full retail without coverage.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
PlushCare is a full-service virtual clinic — primary care, urgent care, mental health, and weight management — rather than a single-purpose "Ozempic in a box" website. It was founded in 2015 by Dr. James Wantuck and Ryan McQuaid, acquired by the health-tech company Accolade in 2021, and Accolade was in turn acquired by Transcarent in a roughly $621 million deal that closed in 2025 (SEC filings). So today PlushCare sits inside a larger employer-and-health-plan benefits company, which matters because it explains the clinic's insurance-first orientation.
The weight-loss program is essentially PlushCare's standard model pointed at obesity care: you see a board-certified physician (the company states its doctors are licensed across all 50 states and average around 15 years of experience), get evaluated, and — if appropriate — receive a prescription sent to a pharmacy. Care continues with follow-up visits and refills.
The single most important distinction versus the wave of GLP-1 startups (Hims, Ro's compounded tiers, Henry Meds, and many smaller clinics) is the product itself: PlushCare prescribes only brand-name, FDA-approved medications. It does not dispense compounded semaglutide or tirzepatide from a 503A/503B pharmacy. This is a meaningful safety and quality decision, especially after the FDA removed semaglutide and tirzepatide from its drug-shortage list in 2024–2025, which sharply curtailed the legal basis for mass-compounding these molecules.
The flow is deliberately built around a real clinical encounter rather than an asynchronous intake form:
Included: physician visits, e-prescriptions, prior-authorization support, in-app messaging, and same/next-day scheduling through the membership. Not included: the medication itself (billed by the pharmacy), and — importantly — there is little to no structured lifestyle program. PlushCare is clinical oversight, not a coaching ecosystem. There is no dedicated dietitian curriculum, food logging, or behavior-change coaching baked into the weight-loss product the way Found, Calibrate, or Noom Med position theirs. If you want a doctor to prescribe and monitor a real branded GLP-1 and you'll handle diet and exercise yourself, that's the fit. If you want hand-holding, it isn't.
This is where buyers get tripped up, because there are three separate line items and the medication line dwarfs the others.
The honest bottom line on cost: if your insurance covers GLP-1s for obesity, PlushCare can be very affordable — realistically ~$75/month all-in (membership + visit copay + medication copay). If it doesn't, you're looking at the membership plus visit fees plus several hundred dollars of medication per month, and potentially $1,000–$1,350/month at brand list price. PlushCare's value proposition lives or dies on coverage and manufacturer savings cards, because the clinic doesn't undercut drug cost with compounding the way some competitors do.
PlushCare states it is in-network with a large number of major plans (Aetna, Cigna, UnitedHealthcare, Anthem, Humana and others). That in-network footprint for the *visit* is a genuine advantage. It does not, however, mean your *medication* is covered — GLP-1 obesity coverage remains spotty and is often denied or restricted by employers and plans regardless of who writes the prescription.
PlushCare can prescribe across the full FDA-approved spectrum, which is broader than many single-drug clinics:
How effective are the headline drugs? The evidence here is among the strongest in modern obesity medicine, and it's worth separating the medication evidence (excellent) from PlushCare's role (it's the prescriber, not the manufacturer):
The key caveat for any patient: these are *average* results in supervised trials, and they generally require ongoing use. Discontinuation studies (e.g., STEP 1 extension data) show substantial weight regain after stopping, which makes the recurring cost question central rather than incidental. PlushCare's clinical model can deliver these drugs legitimately, but it cannot change the fundamental economics of staying on them.
On the dimensions that matter most for safety, PlushCare scores well:
Where the legitimacy conversation gets more nuanced is billing and the membership. PlushCare carries a low Better Business Bureau customer rating (around 2 out of 5), and a recurring complaint theme is exactly what you'd predict from an auto-enrolling subscription: customers report being charged the monthly membership they didn't realize they'd activated, and describe friction canceling. This is not a clinical-safety problem, but it is a real consumer-experience and trust problem you should plan around. Set a calendar reminder before the 30-day free trial ends, and cancel deliberately if you don't intend to keep the membership.
Pros
Cons
Best for: people who want a *legitimate, brand-name* GLP-1 prescription from a real doctor, who have (or expect to qualify for) insurance coverage or a manufacturer savings card, and who are comfortable managing diet and lifestyle on their own. It's also a strong choice for anyone with weight-related comorbidities who values having one clinic handle primary care plus weight management.
Consider skipping if: you're primarily price-shopping and have no GLP-1 coverage — a compounding-based clinic will quote a far lower monthly *medication* number (with the corresponding quality trade-offs you should weigh carefully). Skip it too if you specifically want intensive coaching, dietitian support, or a structured program, since PlushCare's offering is clinical oversight, not lifestyle programming.
PlushCare Weight Loss is a credible, conservatively run telehealth option that does the most important thing right: it puts you in front of a licensed physician and prescribes only FDA-approved, brand-name medications with proven efficacy. For a patient with insurance coverage or a manufacturer savings card, it can be both safe and genuinely affordable. The two things to go in clear-eyed about are that PlushCare provides essentially no lifestyle program, and that its auto-enrolling membership has a well-documented billing-complaint problem — so treat the free trial as a tripwire, not a freebie. If you value clinical legitimacy over the lowest possible sticker price and you've checked your coverage first, it's a reasonable choice; if you're chasing the cheapest GLP-1 regardless of source, look elsewhere and accept the trade-offs.
*This review is informational and independent; HealthVetted accepts no payment for placement. It is not medical advice. GLP-1 medications carry risks (including a boxed warning for thyroid C-cell tumors based on rodent data, and contraindications such as personal/family history of medullary thyroid carcinoma or MEN 2). Discuss your individual situation with a licensed clinician before starting any medication.*
PlushCare itself is a telehealth platform, not a drug. You book a video visit with a board-certified physician who reviews your history, orders an obesity lab panel (typically CBC, a metabolic panel, lipids, A1C, TSH, and insulin, drawn through a lab such as Quest), and, if appropriate, prescribes a GLP-1 medication sent to your pharmacy. The medications work by mimicking gut hormones: semaglutide (Wegovy/Ozempic) activates GLP-1 receptors, while tirzepatide (Zepbound/Mounjaro) activates both GLP-1 and GIP receptors. They slow stomach emptying, reduce appetite, and increase fullness, so you tend to eat less and lose weight.
Active ingredient: Brand-name GLP-1
PlushCare does not run its own trials; efficacy comes from the medications it prescribes. In the STEP 1 trial (NEJM 2021, 1,961 adults without diabetes), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% for placebo, with about 50.5% of users losing at least 15% of their body weight. In the SURMOUNT-1 trial (NEJM 2022, 2,539 adults), tirzepatide (Zepbound) produced mean reductions of about 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg doses over 72 weeks, versus roughly 2.4% for placebo. Results depend on reaching and staying on an effective dose, and weight tends to return if the medication is stopped. Compounded versions are not FDA-approved and have not been tested for the same bioequivalence, so results with them may differ.
A realistic timeline of what PlushCare Weight Loss users typically experience. Individual results vary; this is educational, not medical advice.
You complete a medical-history questionnaire and book a video visit (often same-day, 7 days a week); the consult runs about 15 minutes and a physician confirms whether you qualify for a GLP-1 (generally BMI 30+, or 27+ with a weight-related condition). The first visit is roughly $129 if paying cash, separate from the ~$19.99/month membership. No prescription is guaranteed; clinical eligibility is decided case by case.
PlushCare orders baseline lab work (metabolic panel, A1c/blood sugar, lipids, thyroid, vitamin D) and its care team compiles insurance paperwork, which typically takes 3-7 business days. If a prior authorization is needed it can take up to about 2 weeks. Once approved, brand-name medication (Wegovy, Zepbound, etc.) filled at a retail pharmacy may arrive within a few days; compounded options generally take 7-14 days. Coverage and out-of-pocket cost vary widely by plan.
GLP-1 doses are deliberately started low and stepped up to limit side effects: semaglutide (Wegovy) escalates over roughly 16-17 weeks (0.25 mg up to 2.4 mg), and tirzepatide (Zepbound) over about 20 weeks (2.5 mg up to as high as 15 mg). Nausea is the most common side effect and tends to be worst in the first 1-2 weeks after each dose increase, usually easing within several weeks. Some early appetite reduction and modest weight loss are common, but results differ from person to person.
Most people reach their target maintenance dose and weight loss tends to accelerate after the higher doses are reached. PlushCare typically repeats lab work around the 6-month mark and offers as-needed follow-up visits (each billed to insurance or paid out of pocket, around $99 cash) for dose adjustments and side-effect management, plus 24/7 messaging with the care team. There is no structured coaching program. Individual response varies; not everyone tolerates the full dose.
In the pivotal trials, average weight loss reached about 14.9% over 68 weeks for semaglutide 2.4 mg (STEP-1) and about 20.9% over 72 weeks for tirzepatide 15 mg (SURMOUNT-1). Weight loss commonly plateaus somewhere between roughly month 12 and 18 as the body reaches a new set point. These are trial averages, not guarantees; your results depend on dose tolerated, adherence, diet, and individual biology.
GLP-1 therapy for weight management is generally long-term; stopping often leads to regaining weight, so providers usually continue monitoring and prescribing after you hit your goal. Expect periodic check-in visits (each billed) and ongoing medication costs, which can run roughly $1,000/month without insurance coverage. Discuss any plan to pause or stop with your provider rather than stopping on your own.
The side effects are those of the GLP-1 drugs themselves, not the platform. The most common are gastrointestinal: nausea, vomiting, diarrhea, constipation, and bloating, usually worst when starting or increasing the dose and often easing over time. Less common but serious risks include pancreatitis, gallbladder problems (including gallstones), and dehydration-related kidney injury from severe vomiting. These drugs carry an FDA boxed warning about thyroid C-cell tumors seen in rodents (the relevance to humans is unconfirmed, but they are contraindicated with a history of MTC or MEN 2). Tell your PlushCare doctor about severe or persistent abdominal pain, which can signal pancreatitis, and seek urgent care if it is intense.
Starts at $99/mo from PlushCare.
As of 2026, PlushCare charges a membership of about $19.99/month (often with a free first month) or roughly $99/year, plus consultation fees: about $129 per visit without insurance, or a copay (often $30 or less) with in-network insurance. These fees cover only the platform and doctor; the medication is billed separately. Brand-name GLP-1s can reach roughly $1,000+ per month at full retail if insurance denies coverage, but PlushCare also advertises promotional cash-pay brand pricing at times (for example, Ozempic and Wegovy near $199/month for the first two months, then higher) and offers compounded semaglutide in eligible states at around $149/month for the lowest dose and about $299/month for higher doses, which is paid out of pocket and does not run through insurance. PlushCare can attempt prior authorization for brand drugs, but GLP-1 coverage is never guaranteed and the process can take up to about two weeks. Confirm current pricing at signup, since promotional rates change.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
For US adults who qualify (BMI 30+, or 27+ with a weight-related condition) and want real physician oversight plus access to FDA-approved GLP-1s, PlushCare is a credible, convenient choice with same-day visits. Go in clear-eyed: the membership and visit fees only buy the doctor and the prescription, not the medication, and brand-name GLP-1s remain expensive unless insurance covers them. Watch the auto-renewing membership and per-visit fee so you are not surprised at checkout. This is general information, not medical advice.
Yes. PlushCare is a legitimate telehealth company licensed in all 50 states, where board-certified physicians conduct video visits, order labs, and prescribe GLP-1 medications based on your eligibility. Its physicians are M.D.s rather than nurse practitioners. The main criticisms are about billing and subscription practices and the cost of the medication, not clinical quality.
As of 2026, expect about $19.99/month for membership (often a free first month, or roughly $99/year) plus about $129 per visit without insurance, or a copay with in-network insurance. The GLP-1 medication is billed separately and can range from a few hundred dollars on compounded or promotional cash-pay pricing to roughly $1,000+ per month for brand drugs at full retail without coverage.
Yes. PlushCare physicians can prescribe FDA-approved GLP-1 medications including Wegovy and Zepbound (approved for weight loss) and Ozempic, Mounjaro, Rybelsus, Victoza, Trulicity and others (approved for type 2 diabetes), based on your medical eligibility and labs. In eligible states it can also prescribe compounded semaglutide or tirzepatide as a cash-pay alternative, typically when a brand drug is not covered.
PlushCare is in-network with many major insurance plans for the doctor visit and will attempt a prior authorization for your medication. However, insurance coverage of GLP-1 weight-loss drugs is not guaranteed, prior authorization can take up to about two weeks, and the cash-pay compounded option does not run through insurance at all.
Yes. PlushCare typically orders an obesity lab panel, often including CBC, a metabolic panel, lipids, A1C, TSH, and insulin, before prescribing a GLP-1, to screen for conditions that affect safety. Your doctor reviews the results with you before starting treatment.
Generally, US adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes. People with a personal or family history of medullary thyroid cancer or MEN 2, active pancreatitis, or who are pregnant or breastfeeding should not use these medications. The prescribing doctor makes the final call.
Often the same day, frequently within about 30 minutes of booking. Video visits typically last around 15 minutes, and PlushCare offers appointments in all 50 states.
Some users report difficulty. The membership auto-renews at about $19.99/month, and Better Business Bureau complaints describe surprise charges and trouble canceling or reaching customer support. Cancel through your account before any free trial ends and keep written records to avoid unexpected billing.
It can. PlushCare leads with FDA-approved brand-name GLP-1s, but in eligible states it also offers compounded semaglutide or tirzepatide as a lower-cost cash-pay alternative, usually when a brand drug is unavailable or not covered by insurance. Compounded versions are not FDA-approved, so discuss the trade-offs with your prescriber before choosing one.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Legitimate ways to lower your cost. We don’t sell PlushCare Weight Loss — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
Many brand-name drugs have a manufacturer copay-savings program on the drug’s official site. Check the maker’s website for a current savings card (commercial insurance usually required; government insurance excluded).
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
Same-category options, scored on the same six-axis rubric. Higher is better.